Bayer is moving forward with one of its larger recent manufacturing bets in Mexico. The company says 1.9 billion pesos will go to its plants in Lerma and Orizaba, where it is adding capacity, updating equipment, and preparing for more exports. The spending is part of a wider five-year Mexico plan, but these two sites show where the company sees near-term growth. For Mexico, the story is about more than corporate spending. It is another sign that multinational drugmakers still see the country as a strategic production base.

A bigger share of a longer plan

Bayer said it is moving ahead with 1.9 billion pesos for two plants in Mexico. Most of the money is headed to Lerma in the State of Mexico. The rest is going to Orizaba in Veracruz. The spending is not a new standalone plan. It is part of a broader 3 billion peso investment program announced for Mexico last year and spread over five years. What stands out now is the clearer view of where the money is landing first.

Lerma takes the larger share

At Lerma, Bayer is putting 1.1 billion pesos into expansion and modernization. The plant makes over-the-counter products such as Aspirina and Alka-Seltzer. The company said the project is about 70 percent complete. It expects the work to finish by the end of 2026. Bayer has said the Lerma expansion will lift output for Latin America and North America. It has also tied the project to temporary construction jobs and future permanent positions.

Orizaba strengthens the pharmaceutical side

The other 800 million pesos is earmarked for Orizaba. There, Bayer is upgrading equipment, adding technology, and increasing automation. That site matters because it produces active pharmaceutical ingredients, the core substances used in medicines. Bayer has described Orizaba as one of four global facilities it uses for this kind of production. The investment also covers infrastructure, laboratories, and a new sterile hormonal injectable line.

Why the investment matters

This matters because the two plants do more than serve Mexican shelves. Bayer has repeatedly described Mexico as a base for domestic supply and exports. In Lerma, a large share of output already goes abroad. In Orizaba, the company says it serves Mexico and foreign markets. It is also seeking approvals that would open more sales in Asia and Africa. That gives the investment a wider reach than a routine plant upgrade.

The announcement also fits a wider push to expand pharmaceutical production in Mexico. When Bayer presented its five-year plan in 2025, the federal government grouped it with other industry projects under Plan México. That does not mean policy alone is driving the factory work. It does show the investment arrives as Mexico tries to deepen its role in medicine manufacturing and regional supply chains.

For readers watching Mexico’s economy, the takeaway is direct. Bayer is not treating the country only as a sales market. It is putting more money into production capacity, export reach, and manufacturing infrastructure. With more than a century in Mexico, the company is signaling long-term confidence in its local operations.

With information from El Economista, Bayer de México, Gobierno de México